Enter your email address below and subscribe to our newsletter

Technology

Share your love

Meeting expectations with evolving technology

(Image Credit: AdobeStock) As an ophthalmology resident, I am increasingly meeting patients who underwent LASIK surgery 15 or 20 years ago. They were the early adopters of refractive surgery, thrilled to toss their glasses in their youth. Now in their…

The potential of AI in retina with Daniela Ferrara

This conversation features Daniella Ferrara, Chief Medical Officer for TopCon Healthcare, discussing the transformative potential of artificial intelligence in retinal imaging and ophthalmology. Ferrara, an ophthalmologist and retina specialist with 25 years of experience in retinal imaging innovation. The discussion…

Alcon presenting at APACRS 2025

(Image credit: ©RealityImages/AdobeStock) Alcon announced presentations during the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. The company will showcase four symposia, lead 10 medical affairs scientific exchange presentations, and offer a hands-on experience zone booth.1 APACRS…

Peptide Eye Drops Offer Hope for Dry AMD

Researchers from the Natural Product Drug Development Center at the Korea Institute of Science and Technology (KIST), led by Dr. Moon-Hyeong Seo, have developed an innovative therapeutic agent for dry age-related macular degeneration (AMD) in the form of peptide-based eye…

MicroPulse TLT Proven Effective for Glaucoma

Iridex Corporation, a global leader in laser-based medical systems for glaucoma and retinal disease treatment, has announced the publication of a groundbreaking peer-reviewed study in Ophthalmology Therapy. The study provides compelling evidence of the long-term safety and efficacy of MicroPulse…

4DMT Reveals Preclinical Data on TVE Platform

4D Molecular Therapeutics (4DMT) has announced the publication of preclinical data underscoring the capabilities of its Therapeutic Vector Evolution (TVE) platform. The research focuses on the intravitreal R100 vector and the R100-based genetic medicine 4D-150. This groundbreaking study, titled “Design…

FDA Clears ViGeneron’s VG801 for Stargardt Disease

The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for VG801, ViGeneron’s novel gene therapy candidate designed to treat Stargardt disease and other retinal dystrophies caused by mutations in the ABCA4 gene. This marks…

Stay informed and not overwhelmed, subscribe now!